Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Grillo

Anesthesiology New York, NY Medical Doctor

NPI 1104919265 CMS profile 96113

75 W End Ave Apt P37c, New York, NY 10023

Open in the dashboard

General payments

$4,917

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Grillo of New York, NY is reported in the CMS Open Payments database as having received $4,917 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $719 29
2024 General $915 34
2023 General $560 22
2022 General $615 35
2021 General $816 47
2020 General $236 13
2019 General $1,056 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Grillo
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to John Grillo were reported at $719. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year John Grillo Anesthesiology median Middle half National median
2019 $1,056 $72 $23–$151 $163
2020 $236 $36 $17–$120 $114
2021 $816 $49 $21–$135 $132
2022 $615 $52 $22–$144 $149
2023 $560 $53 $23–$143 $160
2024 $915 $55 $25–$150 $164
2025 $719 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,666 97 payments
  2. QOL Medical, LLC $964 26 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $894 43 payments
  4. UCB, Inc. $401 20 payments
  5. Shire North American Group Inc $245 11 payments
  6. Janssen Biotech, Inc. $137 5 payments
  7. AbbVie, Inc. $110 5 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $93 4 payments
  9. Pfizer Inc. $56 2 payments
  10. Sandoz Inc. $45 2 payments
  11. Other $306 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,905 230 payments
  2. Consulting Fee $12 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,626 95 payments
  2. ENTYVIO $831 40 payments
  3. Sucraid Therapy For Csid $561 14 payments
  4. Cimzia $401 20 payments
  5. GATTEX $263 12 payments
  6. Sucraid Genetic Disease $206 5 payments
  7. Sucraid Therapy For Csid $197 7 payments
  8. STELARA $137 5 payments
  9. HUMIRA $110 5 payments
  10. JARDIANCE $46 2 payments
  11. Other $539 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$26,129

Medicare's payments for the services billed

Medicare patients

165

Average age 77

Services billed

179

97 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 51%
Osteoporosis 33%
Diabetes 28%
Ischemic heart disease 25%
Cancer 24%
Chronic kidney disease 16%
Atrial fibrillation 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $332
$332 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $316
$316 — —
STELARA
  • Janssen Biotech, Inc. $105
$105 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $92
$92 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record